About Jennifer
Jennifer Wilkie is a partner in Gowling WLG's Ottawa office, and an active member of the firm’s Patents, Intellectual Property Litigation & Strategy and Life Sciences groups.Jennifer has over 20 years of experience in the intellectual property field, including over 15 years as a registered patent agent. Her practice has focused primarily on patents, especially patent litigation and patent prosecution, with an emphasis on pharmaceutical and chemical patents. Jennifer regularly acts for clients in patent infringement and patent impeachment matters, as well as judicial review proceedings, including applications under the Patented Medicines (Notice of Compliance) Regulations. She has appeared in the Federal Court and Federal Court of Appeal, as well as the Ontario Courts. Jennifer has acted for many companies, including Novartis, Astellas, Janssen, Bristol-Myers, Merck, Shire and Actelion.Her practice also involves providing strategic advice to clients on achieving optimal patent protection, portfolio management and enforcement. In the pharmaceutical context, this includes advice as to patent listing, innovative drug listing, life cycle management and regulatory requirements under the Food and Drugs Act and Regulations, and under the PMPRB.Jennifer is a regular writer on intellectual property issues, in particular pharmaceutical patent issues. She is also an executive editor of Gowling WLG's PharmaFlash newsletter.
Jennifer Wilkie is a partner in Gowling WLG's Ottawa office, and an active member of the firm’s Patents, Intellectual Property Litigation & Strategy and Life Sciences groups.Jennifer has over 20 years of experience in the intellectual property field, including over 15 years as a registered patent agent. Her practice has focused primarily on patents, especially patent litigation and patent prosecution, with an emphasis on pharmaceutical and chemical patents. Jennifer regularly acts for clients in patent infringement and patent impeachment matters, as well as judicial review proceedings, including applications under the Patented Medicines (Notice of Compliance) Regulations. She has appeared in the Federal Court and Federal Court of Appeal, as well as the Ontario Courts. Jennifer has acted for many companies, including Novartis, Astellas, Janssen, Bristol-Myers, Merck, Shire and Actelion.Her practice also involves providing strategic advice to clients on achieving optimal patent protection, portfolio management and enforcement. In the pharmaceutical context, this includes advice as to patent listing, innovative drug listing, life cycle management and regulatory requirements under the Food and Drugs Act and Regulations, and under the PMPRB.Jennifer is a regular writer on intellectual property issues, in particular pharmaceutical patent issues. She is also an executive editor of Gowling WLG's PharmaFlash newsletter.
Jennifer Wilkie is a partner in Gowling WLG's Ottawa office, and an active member of the firm’s Patents, Intellectual Property Litigation & Strategy and Life Sciences groups.
Jennifer has over 20 years of experience in the intellectual property field, including over 15 years as a registered patent agent. Her practice has focused primarily on patents, especially patent litigation and patent prosecution, with an emphasis on pharmaceutical and chemical patents. Jennifer regularly acts for clients in patent infringement and patent impeachment matters, as well as judicial review proceedings, including applications under the Patented Medicines (Notice of Compliance) Regulations. She has appeared in the Federal Court and Federal Court of Appeal, as well as the Ontario Courts. Jennifer has acted for many companies, including Novartis, Astellas, Janssen, Bristol-Myers, Merck, Shire and Actelion.
Her practice also involves providing strategic advice to clients on achieving optimal patent protection, portfolio management and enforcement. In the pharmaceutical context, this includes advice as to patent listing, innovative drug listing, life cycle management and regulatory requirements under the Food and Drugs Act and Regulations, and under the PMPRB.
Jennifer is a regular writer on intellectual property issues, in particular pharmaceutical patent issues. She is also an executive editor of Gowling WLG's PharmaFlash newsletter.
